Thomas Haldis, DO
Cardiovascular Disease · Fargo, NDNPI 1588681449
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,000 of the $36,555 with a category attached, or 60.2%. 12 manufacturers reported payments, led by AstraZeneca at 52.8% of the total. Reporting peaked in 2021 at $16,079 and has fallen 72.2% since, to $4,469 in 2025. Among cardiovascular disease clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $152.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$19K
- Medtronic$6K
- Edwards Lifesciences$4K
- Abbott$3K
- Pfizer$3K
- Boston Scientific$475
- plus $658 from 6 others
Across 123 payments — averaging $4389.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$396K
- Medtronic$112K
- CSL Behring$16K
- Biotronik Inc.$10K
- Novartis$6K
What the payments were for
- Speaking & faculty fees$22,00060%
- Travel & lodging$6,81419%
- Food & beverage$7,64021%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $19,296 |
| Medtronic(2 entities) | 118 | $6,022 |
| Edwards Lifesciences | 38 | $3,639 |
| Abbott | 22 | $3,415 |
| Pfizer | 2 | $3,050 |
| Boston Scientific | 17 | $475 |
| Biotronik Inc. | 8 | $268 |
| Shockwave Medical, Inc | 8 | $222 |
| Abiomed | 1 | $63 |
| Bard Peripheral Vascular, Inc. | 1 | $57 |
| Penumbra, Inc. | 1 | $33 |
| Philips North America LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,555 in reported general payments places this provider in the 90th percentile of 35 cardiovascular disease providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 91 | $75,414 |
| BrilintaTicagrelor | 18 | $11,761 |
| Enoxaparin Sodium | 22 | $1,693 |
| Warfarin Sodium | 198 | $1,425 |
| JantovenWarfarin Sodium | 127 | $1,131 |
| Nebivolol Hcl | 15 | $777 |
| Metoprolol Succinate | 66 | $774 |
| Rosuvastatin Calcium | 59 | $584 |
| Bumetanide | 12 | $533 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 26 | $465 |
| Losartan Potassium | 59 | $454 |
| Lisinopril | 46 | $418 |
| Atorvastatin Calcium | 40 | $414 |
| Carvedilol | 31 | $352 |
| Spironolactone | 22 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $3,050 | $75,41491 claims |
| AstraZenecaBrilinta | $19,296 | $11,76118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 35 cardiovascular disease providers in North Dakota.
Other cardiovascular disease in Fargo
- Matthew GlogozaFargo$36K
- Jason GoFargo$15K
- Padmaraj DuvvuriFargo$7K
- Brian GrondahlFargo$6K
- Ahmed AbuzaanonaFargo$4K
- Aaron SmithFargo$2K
- Ralph MoralesFargo$1K
- David ClardyFargo$967
- Abdallah MansourFargo$614
- Oluwaseun FashanuFargo$445
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.